A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R WallersteinM Ewer

Abstract

To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP). We performed a phase II trial of high-dose mitoxantrone 30 mg/m2, etoposide 200 mg/m2 every 12 hours x 6, and thiotepa 250 mg/m2 x 3 days (MVT) in 31 patients with heavily pretreated metastatic breast cancer and one with locally advanced chemotherapy-refractory breast cancer. These patients were ineligible for high-dose CVP chemotherapy because of the amount of prior treatment and poor-response status. Of the 32 patients, 14 responded to cycle 1, did not experience any grade 4 toxicity, and received a second cycle of MVT. Overall, seven of 31 patients achieved a complete response (CR; 23%). Four of the 14, who were partial responders to the first cycle, achieved a CR after the second cycle. The overall response rate was 19 of 31 (61%) with an overall median freedom from progression of 4 to 5 months and an overall median survival of 9 months. Toxicity consisted primarily of mucositis (grade 3 or 4 in 69%). The results indicate tha...Continue Reading

Citations

Sep 1, 2000·Bone Marrow Transplantation·L E DamonC A Linker
Mar 15, 2003·Blood·Chandini M ThirukkumaranDonald G Morris
Nov 3, 2011·Bone Marrow Research·Chandini M Thirukkumaran, Don G Morris
Apr 1, 1996·Annals of Medicine·H Joensuu
Dec 4, 2003·Bone Marrow Transplantation·N KrögerUNKNOWN University of California, San Francisco
Jan 1, 1993·Breast Cancer Research and Treatment·G SpitzerW Velasquez
Jan 1, 1995·Cancer Investigation·L VahdatJ Crown
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PatnaikM Crump
Dec 28, 1999·Acta Oncologica·J Bergh
Sep 30, 2000·Stem Cells·D V JonesG Fyfe
Sep 28, 1998·Cancer Chemotherapy and Pharmacology·M S Tallman, W J Gradishar
Apr 24, 2007·Bone Marrow Transplantation·C M ThirukkumaranD G Morris
Nov 2, 1999·Cancer Treatment Reviews·N KrögerA R Zander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.